Hospital Acquired Pneumonia Drugs Market Will Experience a Noticeable Growth during the Forecast Period

Hospital Acquired Pneumonia Drugs Market Will Experience a Noticeable Growth during the Forecast Period

According to a new market report published by Research Corridor “Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2014 – 2020” six phase III drugs would generate total revenue of USD 3.8 billion by 2020.

Hospital-acquired infections also called healthcare-associated infections or nosocomial infections have raised serious concerns due to multidrug resistance shown by microorganisms. Multidrug-resistant organisms are immune to conventional antibiotics, hence very difficult to treat. Pneumonia accounts for over 22% of all hospital-acquired infections. Since hospital-acquired pneumonia is mainly caused as a result of prolonged exposure to the ventilator, it is also called as ventilator-associated pneumonia. The infection is common in immunocompromised patients, post-surgical infections, enteral feeding, and in elderly and infant patients. Various gram-positive, as well as gram-negative bacteria, are known to cause hospital-acquired pneumonia. Major causative agents include methicillin-resistant S. aureus (MRSA), multidrug-resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) is found to be a major causative agent of nosocomial pneumonia in new borne.

Currently, there are five investigational drugs and one vaccine in stage III clinical trials, while ten other candidates in the early stage. Phase III candidates include Tedizolid phosphate and Ceftolozane/tazobactam by Cubist Pharmaceuticals, Ceftazidime/avibactam by AstraZeneca PLC, Amikacin inhale by Bayer Healthcare, Plazomicin by Achaogen, Inc. and Synflorix by GlaxoSmithKline. The majority of these drugs are expected to be launched by 2017. Analysis reveals that the majority of the candidates in the late stage are biological drugs. This indicates a paradigm shift from traditional antibiotic therapy to more sophisticated biological drug therapy. Aridis Pharmaceuticals holds a strong monoclonal antibody pipeline with four candidates for the treatment of hospital-acquired pneumonia which was acquired from Kenta Biotech in 2013.

Growing drug resistance has been a major concern in hospitals globally. According to a report published by the Centers for Disease Control and Prevention (CDC), which considers the U.S. population to study, 63% of Acinetobacter is considered multidrug-resistant. Methicillin resistant Staphylococcus aureus (MRSA) is one of the most hazardous organisms causing ventilator-associated pneumonia. CDC estimates that over 80,400 MRSA infections occurred in 2011, of which more than 11,000 patients died. Furthermore, the World Health Organization (WHO) suggests that the prevalence of nosocomial infections is higher in low and middle-income countries. This suggests that the conditions are more alarming in these regions. In addition, the rate of hospital acquired infections have been declining since the recent past according to statistics published by Office National Statistics, U.K.

Key companies in the market include Achaogen, Inc., Aridis Pharmaceutical, AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer Healthcare, Cubist Pharmaceutical, GlaxoSmithKline, Meiji Seika Pharma Co., Ltd., Merck & Co., and Valneva SE.

Request a report sample for Global Hospital Acquired Pneumonia Drugs Market @ https://www.researchcorridor.com/request-sample/?id=27540

Hospital-Acquired Pneumonia Drug Pipeline is as follows:

Late Stage Candidates (Phase III)

• Tedizolid phosphate
• Ceftolozane/tazobactam
• Ceftazidime/avibactam
• Amikacin inhale
• Plazomicin
• Synflorix

Early Stage Candidates (Phase II, Phase I and Preclinical Trials)

• AR-101 or KBPA101
• GSK 2189242A
• BAL30072
• MEDI4893
• AR 301 or KBSA301
• ME1100
• V114
• AR-104 or KBPA104
• AR-201 or KBRV201
• AR-401 or KBAB401